Scribd Logo
Upload

Welcome to Scribd!

  • 33 views

    Biocon PGDM 10

    Uploaded by

    Arunima Chatterjee
    Biocon is an Indian biopharmaceutical company headquartered in Bangalore. It delivers innovative biopharmaceutical solutions through discovery, development, and commercialization. Biocon leverages India's low-cost base and scientific talent. It has a robust drug pipeline led by monoclonal antibodies. Biocon remains committed to scaling new heights in science and achieving affordable medicine. Its subsidiaries include Syngene, Clinigene, and joint ventures like BBPL and NeoBiocon. Biocon plans to establish pharmacovigilance services and conduct early clinical trials to expand in oncology, asthma, and rheumatoid arthritis.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPT, PDF, TXT or read online from Scribd

    Biocon PGDM 10

    Uploaded by

    Arunima Chatterjee
    33 views4 pages
    Biocon is an Indian biopharmaceutical company headquartered in Bangalore. It delivers innovative biopharmaceutical solutions through discovery, development, and commercialization. Biocon leverages India's low-cost base and scientific talent. It has a robust drug pipeline led by monoclonal antibodies. Biocon remains committed to scaling new heights in science and achieving affordable medicine. Its subsidiaries include Syngene, Clinigene, and joint ventures like BBPL and NeoBiocon. Biocon plans to establish pharmacovigilance services and conduct early clinical trials to expand in oncology, asthma, and rheumatoid arthritis.

    Original Title

    Biocon_PGDM_10

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PPT, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Biocon is an Indian biopharmaceutical company headquartered in Bangalore. It delivers innovative biopharmaceutical solutions through discovery, development, and commercialization. Biocon leverages India's low-cost base and scientific talent. It has a robust drug pipeline led by monoclonal antibodies. Biocon remains committed to scaling new heights in science and achieving affordable medicine. Its subsidiaries include Syngene, Clinigene, and joint ventures like BBPL and NeoBiocon. Biocon plans to establish pharmacovigilance services and conduct early clinical trials to expand in oncology, asthma, and rheumatoid arthritis.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    33 views4 pages

    Biocon PGDM 10

    Uploaded by

    Arunima Chatterjee
    Biocon is an Indian biopharmaceutical company headquartered in Bangalore. It delivers innovative biopharmaceutical solutions through discovery, development, and commercialization. Biocon leverages India's low-cost base and scientific talent. It has a robust drug pipeline led by monoclonal antibodies. Biocon remains committed to scaling new heights in science and achieving affordable medicine. Its subsidiaries include Syngene, Clinigene, and joint ventures like BBPL and NeoBiocon. Biocon plans to establish pharmacovigilance services and conduct early clinical trials to expand in oncology, asthma, and rheumatoid arthritis.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    of 4

    BIOCON – COMPANY PROFILE

    Website:-http://www.biocon.com/
    Board No:- 91 80 2808 2808 / 91 80 4014 4014
    Location (Headquarters) : Bangalore
    STRICTLY PRIVATE AND CONFIDENTIAL

    Institute for Technology & Management


    BIOCON– Company profile

    Company
    Company Overview Financial
    Overview Financial highlights
    highlights
    •Biocon is a fully integrated healthcare company that delivers
    innovative biopharmaceutical solutions.
    •From discovery to development and commercialization, it has the
    defining science, cost-effective drug development capabilities and
    significant manufacturing capacity to move ideas to market.
    •Leveraging India’s globally competitive cost base and exceptional
    scientific people resource, it is advancing its in-house R&D
    programs, while also providing custom and clinical research services
    to international pharmaceutical and biotechnology majors through
    our subsidiary companies, Syngene and Clinigene.
    •Biocon has rapidly developed a robust drug pipeline, led by
    monoclonal antibodies and several other molecules at exciting
    stages in the biopharmaceutical value chain. With the successful
    commercial launch of our first anti-cancer drug and several
    promising discovery partnerships in the clinic, it remains committed
    to scaling new heights in frontier science and achieving new
    milestones in affordable medicine.

    Distribution
    Distribution of
    of revenue
    revenue by
    by segments
    segments
    Share
    Share holding
    holding pattern
    pattern 2010 2009
    2010
    BIOCON – COMPANY PROFILE

    Source: Company Annual reports as of March 31 2009

    JOHN KEELLS 1 Institute for Technology & Management


    Biocon – Company profile

    Management
    Management Tree
    Tree
    BIOCON – COMPANY PROFILE

    JOHN KEELLS 1 Institute for Technology & Management


    Biocon – Company profile

    Subsidiaries Recent
    Subsidiaries Recent M&A
    M&A
    CIMAB
    •An important development this fiscal was the conclusion of the
    agreement for acquisition of 49% equity stake of its Cuban partner
    CIMAB S.A. in Biocon Biopharmaceuticals Pvt. ltd. (BBPL), a seven
    year old biomanufacturing joint venture.
    IDL
    Another key acquisition made this fiscal was IDL Specialty
    Chemicals Ltd. near Hyderabad.
    NeoBiocon
    •NeoBiocon, its Dubai based JV with Abu Dhabi pharmaceutical
    manufacturer Neopharma, has successfully registered our breast
    cancer treatment drug AbraxaneR in the formulary of all major
    cancer institutes in UAE.

    Future
    Future Plans
    Plans &
    & Outlook
    Outlook
    The Indian pharmaceutical market is estimated to grow at over 17%
    per annum and presents a good market opportunity for the
    company.

    Biocon’s future plans include:


    • Establishing pharmacovigilance services.
    • Initiating early phase studies (PK and
    Phase I) in the areas of oncology, asthma
    BIOCON – COMPANY PROFILE

    and rheumatoid arthritis as part of human pharmacology services.

    JOHN KEELLS 1 Institute for Technology & Management

    You might also like